NEO
Income statement / Annual
Last year (2025), Neogenomics Inc.'s total revenue was $727.33 M,
an increase of 10.11% from the previous year.
In 2025, Neogenomics Inc.'s net income was -$108.03 M.
See Neogenomics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$727.33 M |
$660.57 M |
$591.64 M |
$509.73 M |
$484.33 M |
$444.45 M |
$408.83 M |
$276.74 M |
$240.25 M |
$244.08 M |
| Cost of Revenue |
$444.79 M
|
$370.47 M
|
$347.04 M
|
$321.83 M
|
$297.27 M
|
$258.56 M
|
$211.99 M
|
$149.48 M
|
$138.30 M
|
$133.70 M
|
| Gross Profit |
$282.54 M
|
$290.10 M
|
$244.60 M
|
$187.90 M
|
$187.06 M
|
$185.89 M
|
$196.84 M
|
$127.27 M
|
$101.96 M
|
$110.38 M
|
| Gross Profit Ratio |
0.39
|
0.44
|
0.41
|
0.37
|
0.39
|
0.42
|
0.48
|
0.46
|
0.42
|
0.45
|
| Research and Development Expenses |
$37.08 M
|
$31.16 M
|
$27.31 M
|
$30.33 M
|
$21.87 M
|
$8.23 M
|
$8.49 M
|
$3.00 M
|
$3.64 M
|
$4.65 M
|
| General & Administrative Expenses |
$273.34 M
|
$225.87 M
|
$209.12 M
|
$210.59 M
|
$221.35 M
|
$143.79 M
|
$127.99 M
|
$84.82 M
|
$88.76 M
|
$63.93 M
|
| Selling & Marketing Expenses |
$92.01 M
|
$84.63 M
|
$70.84 M
|
$67.32 M
|
$62.59 M
|
$47.86 M
|
$47.35 M
|
$29.40 M
|
$24.00 M
|
$23.91 M
|
| Selling, General & Administrative Expenses |
$365.34 M
|
$310.49 M
|
$279.96 M
|
$277.91 M
|
$283.94 M
|
$191.66 M
|
$175.34 M
|
$114.22 M
|
$113.30 M
|
$87.84 M
|
| Other Expenses |
-$53.80 M
|
$40.55 M
|
$45.07 M
|
$37.29 M
|
$0.00
|
$0.00
|
$0.00
|
$14.00 K
|
$1.06 M
|
$3.46 M
|
| Operating Expenses |
$348.62 M
|
$382.21 M
|
$352.34 M
|
$345.52 M
|
$305.81 M
|
$199.89 M
|
$183.83 M
|
$117.23 M
|
$99.05 M
|
$95.95 M
|
| Cost And Expenses |
$793.41 M
|
$752.67 M
|
$699.38 M
|
$667.35 M
|
$603.08 M
|
$458.44 M
|
$395.82 M
|
$266.70 M
|
$237.35 M
|
$241.51 M
|
| Interest Income |
$9.07 M
|
$18.43 M
|
$16.90 M
|
$6.08 M
|
$3.14 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Interest Expense |
$3.75 M
|
$6.62 M
|
$6.91 M
|
$7.58 M
|
$8.22 M
|
$7.02 M
|
$3.71 M
|
$6.23 M
|
$5.54 M
|
$10.00 M
|
| Depreciation & Amortization |
$67.82 M
|
$72.55 M
|
$72.58 M
|
$69.43 M
|
$53.35 M
|
$41.89 M
|
$30.27 M
|
$21.73 M
|
$22.59 M
|
$23.21 M
|
| EBITDA |
-$38.69 M |
-$1.51 M |
-$17.61 M |
-$82.33 M |
$46.50 M |
$34.85 M |
$37.63 M |
$31.79 M |
$26.55 M |
$25.36 M |
| EBITDA Ratio |
-0.05
|
-0
|
-0.03
|
-0.16
|
0.1
|
0.08
|
0.09
|
0.11
|
0.11
|
0.1
|
| Operating Income Ratio |
-0.09
|
-0.14
|
-0.18
|
-0.31
|
-0.25
|
-0.03
|
0.03
|
0.04
|
0.01
|
0.01
|
| Total Other Income/Expenses Net |
-$44.19 M
|
$11.43 M
|
$10.64 M
|
-$1.72 M
|
$103.68 M
|
-$64.00 K
|
-$9.36 M
|
-$6.22 M
|
-$5.55 M
|
-$10.00 M
|
| Income Before Tax |
-$110.27 M
|
-$80.68 M
|
-$97.10 M
|
-$159.34 M
|
-$15.08 M
|
-$14.06 M
|
$3.65 M
|
$3.82 M
|
-$2.65 M
|
-$7.42 M
|
| Income Before Tax Ratio |
-0.15
|
-0.12
|
-0.16
|
-0.31
|
-0.03
|
-0.03
|
0.01
|
0.01
|
-0.01
|
-0.03
|
| Income Tax Expense |
-$2.24 M
|
-$1.95 M
|
-$9.13 M
|
-$15.09 M
|
-$6.73 M
|
-$18.23 M
|
-$4.36 M
|
$1.18 M
|
-$2.25 M
|
-$1.70 M
|
| Net Income |
-$108.03 M
|
-$78.73 M
|
-$87.97 M
|
-$144.25 M
|
-$8.35 M
|
$4.17 M
|
$8.01 M
|
$2.64 M
|
-$396.00 K
|
-$6.14 M
|
| Net Income Ratio |
-0.15
|
-0.12
|
-0.15
|
-0.28
|
-0.02
|
0.01
|
0.02
|
0.01
|
-0
|
-0.03
|
| EPS |
-4.2 |
-3.1 |
-3.5 |
-5.8 |
-0.35 |
0.19 |
0.4 |
0.14 |
-0.025 |
-0.39 |
| EPS Diluted |
-4.2 |
-3.1 |
-3.5 |
-5.8 |
-0.35 |
0.19 |
0.39 |
0.14 |
-0.025 |
-0.4 |
| Weighted Average Shares Out |
$25.62 M
|
$25.33 M
|
$25.10 M
|
$24.84 M
|
$23.99 M
|
$21.72 M
|
$20.09 M
|
$18.31 M
|
$15.89 M
|
$15.71 M
|
| Weighted Average Shares Out Diluted |
$25.62 M
|
$25.33 M
|
$25.10 M
|
$24.84 M
|
$23.99 M
|
$22.36 M
|
$20.72 M
|
$18.31 M
|
$15.89 M
|
$15.51 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
